ORKA
Price
$82.11
Change
+$4.83 (+6.25%)
Updated
Oct 9 closing price
Capitalization
5.57B
38 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$24.63
Change
+$0.13 (+0.53%)
Updated
Oct 9 closing price
Capitalization
1.9B
29 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORKA vs XNCR

ORKA vs XNCR Comparison Chart in %
View a ticker or compare two or three
VS
ORKA vs. XNCR commentary
Oct 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORKA is a Hold and XNCR is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ORKA vs XNCR: Fundamental Ratings
ORKA
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORKA's Valuation (39) in the null industry is somewhat better than the same rating for XNCR (88) in the Biotechnology industry. This means that ORKA’s stock grew somewhat faster than XNCR’s over the last 12 months.

ORKA's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that ORKA’s stock grew similarly to XNCR’s over the last 12 months.

ORKA's SMR Rating (94) in the null industry is in the same range as XNCR (97) in the Biotechnology industry. This means that ORKA’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's Price Growth Rating (35) in the Biotechnology industry is in the same range as ORKA (37) in the null industry. This means that XNCR’s stock grew similarly to ORKA’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ORKA (100) in the null industry. This means that XNCR’s stock grew significantly faster than ORKA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORKAXNCR
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bearish Trend 3 days ago
67%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
84%
COMPARISON
Comparison
Oct 11, 2026
Stock price -- (ORKA: $82.11 vs. XNCR: $24.63)
Brand notoriety: ORKA and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORKA: 171% vs. XNCR: 69%
Market capitalization -- ORKA: $5.57B vs. XNCR: $1.9B
ORKA [@Biotechnology] is valued at $5.57B. XNCR’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORKA’s FA Score shows that 0 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).

  • ORKA’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ORKA and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORKA’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 2 bullish TA indicator(s).

  • ORKA’s TA Score: 4 bullish, 6 bearish.
  • XNCR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ORKA is a better buy in the short-term than XNCR.

Price Growth

ORKA (@Biotechnology) experienced а -2.85% price change this week, while XNCR (@Biotechnology) price change was -0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.51%. For the same industry, the average monthly price growth was -13.43%, and the average quarterly price growth was -4.26%.

Reported Earning Dates

ORKA is expected to report earnings on Nov 18, 2026.

XNCR is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ORKA
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CAGE29.930.35
+1.17%
Calamos Autocallable Growth ETF (CAGE)
JOUL23.000.13
+0.57%
Corgi High Voltage Grid Equipment ETF (JOUL)
FMY11.06N/A
N/A
FIRST TRUST MORTGAGE Income FUND
FPE17.06-0.02
-0.12%
First Trust Preferred Securities & Income ETF (FPE)
SIXH44.05-0.25
-0.56%
ETC 6 Meridian Hedged Equity Index Option ETF (SIXH)

ORKA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORKA
1D Price
Change %
ORKA100%
+6.25%
SYRE - ORKA
54%
Loosely correlated
+7.25%
CGON - ORKA
44%
Loosely correlated
+0.89%
XNCR - ORKA
41%
Loosely correlated
+0.53%
ENTA - ORKA
41%
Loosely correlated
+3.31%
JBIO - ORKA
41%
Loosely correlated
+1.70%
More